Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Jeffrey R, Sachs"'
Autor:
Josiah Ryman, Jeffrey R. Sachs, Natalie Banniettis, Thomas Weiss, Maurice Ahsman, Ka Lai Yee, Jessica Weaver
Publikováno v:
Expert Review of Vaccines, Vol 23, Iss 1, Pp 467-473 (2024)
Background Next generation, higher valency pneumococcal conjugate vaccines (PCVs) are assessed and licensed by comparing the immune response across serotypes shared with the PCVs that are standard of care for prevention of pneumococcal disease.Method
Externí odkaz:
https://doaj.org/article/da5b7b5fa7ff48d19e008136d16f17f4
Publikováno v:
Expert Review of Vaccines, Vol 23, Iss 1, Pp 60-68 (2024)
Background Next-generation, higher-valency pneumococcal conjugate vaccines (PCVs), 15-valent PCV V114 and 20-valent PCV (PCV20), have been assessed by comparing their immune responses across serotypes shared with the 13-valent PCV (PCV13). Without ef
Externí odkaz:
https://doaj.org/article/95e52e182b40446d82a5d7caa306b2c9
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-11 (2024)
Abstract Understanding potential differences in vaccine-induced protection between demographic subgroups is key for vaccine development. Vaccine efficacy evaluation across these subgroups in phase 2b or 3 clinical trials presents challenges due to la
Externí odkaz:
https://doaj.org/article/61632a4fc2954cfe86bdfc29ff38b87d
Publikováno v:
BMC Medical Research Methodology, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Background Vaccine efficacy (VE) assessed in a randomized controlled clinical trial can be affected by demographic, clinical, and other subject-specific characteristics evaluated as baseline covariates. Understanding the effect of covariates
Externí odkaz:
https://doaj.org/article/02fd0993cd9e481f9c476bec0b21cf57
Publikováno v:
npj Vaccines, Vol 7, Iss 1, Pp 1-7 (2022)
Abstract The strength of the immune response, as measured by antibody concentrations, varies between pneumococcal conjugate vaccines (PCVs). Linking immunogenicity and effectiveness is necessary to assess whether changes in immune response from curre
Externí odkaz:
https://doaj.org/article/e330ffd1d59845498eda3101f78ba2fa
Autor:
Julie Dudášová, Regina Laube, Chandni Valiathan, Matthew C. Wiener, Ferdous Gheyas, Pavel Fišer, Justina Ivanauskaite, Frank Liu, Jeffrey R. Sachs
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-14 (2021)
Abstract Vaccine efficacy is often assessed by counting disease cases in a clinical trial. A new quantitative framework proposed here (“PoDBAY,” Probability of Disease Bayesian Analysis), estimates vaccine efficacy (and confidence interval) using
Externí odkaz:
https://doaj.org/article/415ecc810f6745a2bf96f13f021d869a
Autor:
Bhargava Kandala, Nele Plock, Akshita Chawla, Anna Largajolli, Seth Robey, Kenny Watson, Raj Thatavarti, Sheri A. Dubey, S.Y. Amy Cheung, Rik de Greef, Julie Stone, Jeffrey R. Sachs
Publikováno v:
EBioMedicine, Vol 84, Iss , Pp 104264- (2022)
Summary: Background: The COVID-19 pandemic has increased the need for innovative quantitative decision tools to support rapid development of safe and efficacious vaccines against SARS-CoV-2. To meet that need, we developed and applied a model-based m
Externí odkaz:
https://doaj.org/article/de1aa37726f44b35900d070763f50f39
Autor:
Daniel I. S. Rosenbloom, Julie Dudášová, Casey Davis, Radha A. Railkar, Nitin Mehrotra, Jeffrey R. Sachs
Publikováno v:
Vaccines, Vol 11, Iss 9, p 1501 (2023)
In vaccine efficacy trials, inaccurate counting of infection cases leads to systematic under-estimation—or “dilution”—of vaccine efficacy. In particular, if a sufficient fraction of observed cases are false positives, apparent efficacy will b
Externí odkaz:
https://doaj.org/article/9338473b398c4b5fa038fff778f3ca24
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 9, Pp 1092-1106 (2021)
Abstract Pharmacometric models can enhance clinical decision making, with covariates exposing potential contributions to variability of subpopulation characteristics, for example, demographics or disease status. Intuitive visualization of models with
Externí odkaz:
https://doaj.org/article/c21fd9582c8f4d6bb77d5556f2d45d1d
Autor:
Jonathan A. Robbins, Dereck Tait, Qinlei Huang, Sheri Dubey, Tami Crumley, Josee Cote, Julie Luk, Jeffrey R. Sachs, Kathryn Rutkowski, Harriet Park, Robert Schwab, William Joseph Howitt, Juan Carlos Rondon, Martha Hernandez-Illas, Terry O'Reilly, William Smith, Jakub Simon, Cathy Hardalo, Xuemei Zhao, Richard Wnek, Alethea Cope, Eseng Lai, Paula Annunziato, Dalya Guris, S. Aubrey Stoch
Publikováno v:
EBioMedicine, Vol 82, Iss , Pp 104138- (2022)
Summary: Background: Vaccines against COVID-19 are needed to overcome challenges associated with mitigating the global pandemic. We report the safety and immunogenicity of V590, a live recombinant vesicular stomatitis virus-based COVID-19 vaccine can
Externí odkaz:
https://doaj.org/article/a44da410c7ec4f96838eaf6361e76d18